Aspirin Delays the Development/Progression of Neuroendocrine Pancreatic Neoplasms and Prolongs Survival in a Transgenic Mouse Model of Islet Cell Tumors

#746

Introduction: So far, there are no chemopreventive strategies for neuroendocrine pancreatic neoplasms.

Aim(s): Based on studies of our own group, where we invented aspirin as a chemopreventive agent in pancreatic cancer, we now evaluated the chemopreventive potential of aspirin in a transgenic mouse model of islet cell tumors (Rip1Tag2 mice).

Materials and methods: Rip1Tag2 mice were treated with aspirin (50 mg/kg/bodyweight/day) or with placebo (NaCl). Drug treatment started at the age of five weeks. The intervention group was treated from the 5th until the 13th week and than sacrified. The mice of the survival group were treated from the fifth week until they reached an earlier defined abort criteria (e.g. apathy, ascites, etc.). The effect of aspirin was evaluated by histopathological analyses. Survival was calculated by a log rank analysis. A value of P < 0.05 was considered to indicate statistical significance.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Fendrich V

Authors: Fendrich V, Manoharan J, Lopez C, Waldmann J, Bartsch D,

Keywords: neuroendocrine pancreatic tumors, aspirin, chemoprevention,